Decrease of FGF19 contributes to the increase of fasting glucose in human in an insulin-independent manner

Zhang, J.; Li, Hongtao; Bai, Ningning; Xu, Yu; Song, Qianqian; Zhang, Lenan; Wu, Guangyu; Chen, S.; Hou, Xuhong; Wang, C.; Li, Wei; Xu, Aimin; Fang, Qichen; Jia, Weiping

doi:10.1007/s40618-019-01018-5

Cited by 14 publications

(14 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…e mechanisms of the effects of FGF19 on metabolism have been thoroughly studied. Zhang et al demonstrated that a reduction in FGF19 concentration has effects on glucose effectiveness and hepatic glucose production, which leads to an increase in fasting blood glucose [6]. FGF15/19 have additive effects to insulin to reduce hepatic gluconeogenesis by inhibiting the cAMP-response element-binding protein-peroxisome proliferator-activated receptor coactivator-1a signaling cascade after a meal [12].…”

Section: Mechanisms Of the Effects Of Fgf19 On Glucose Metabolism Andmentioning

confidence: 99%

“…Specifically, a meta-analysis suggested that diabetes increases the risk of liver and pancreatic cancer [3], and a majority of studies have also shown that diabetes is an independent risk factor for the development and progression of HCC [4,5]. Interestingly, both fibroblast growth factor (FGF) 19 and bile acids play important roles in the pathogenesis of T2DM and HCC [6][7][8].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum Fibroblast Growth Factor 19 and Total Bile Acid Concentrations Are Potential Biomarkers of Hepatocellular Carcinoma in Patients with Type 2 Diabetes Mellitus

Sun

Zhu

Zhao

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Purpose. Type 2 diabetes mellitus (T2DM) carries a high risk of hepatocellular carcinoma (HCC). Both serum fibroblast growth factor 19 (FGF19) and bile acid concentrations are associated with T2DM and HCC. We aimed at evaluating the relationships between FGF19 and bile acid concentrations and HCC in patients with T2DM. Methods. Twenty-seven healthy volunteers (control group), 27 patients with T2DM (T2DM group), 16 patients with newly diagnosed HCC (HCC group), and 10 T2DM patients with newly diagnosed HCC (T2DM-HCC group) were studied at the Affiliated Hospital of Nantong University between June 2016 and June 2017. The serum concentrations of serum FGF19 and total bile acids (TBA) were measured in all the participants. Correlation analysis and multiple stepwise regression analysis of the FGF19 and TBA concentrations were performed in all the participants and in the four groups. Results. The concentrations of FGF19 were 220.5 pg/ml, 185.1 pg/ml, 115.8 pg/ml, and 70.4 pg/ml in the HCC, T2DM-HCC, control, and T2DM groups, respectively (p<0.001), and the TBA concentrations were 21.75 μmol/l, 14.25 μmol/l, 3.6 μmol/l, and 3.1 μmol/l (p<0.001). There were positive correlations between the FGF19 and TBA concentrations across all the participants (r = 0.777; p<0.001), and in the control (r = 0.400; p=0.039), T2DM (r = 0.477; p=0.012), HCC (r = 0.684; p=0.003), and T2DM-HCC (r = 0.673; p=0.033) groups. Conclusions. Simultaneous increase of serum FGF19 and TBA levels may be used as indicators of HCC screening at early stage in patients with T2DM.

show abstract

Section: Mechanisms Of the Effects Of Fgf19 On Glucose Metabolism Andmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Serum Fibroblast Growth Factor 19 and Total Bile Acid Concentrations Are Potential Biomarkers of Hepatocellular Carcinoma in Patients with Type 2 Diabetes Mellitus

Sun

Zhu

Zhao

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Interestingly, FGF19 levels were negatively correlated with fasting plasma glucose (31) and shown to be decreased in impaired fasting glucose, obesity, T2D, and NAFLD subjects. This suggest a physiological role for endogenous FGF19 in glucose metabolism and insulin sensitivity.…”

Section: Discussionmentioning

confidence: 99%

Dynamic Changes in Circulating Endocrine FGF19 Subfamily and Fetuin-A in Response to Intralipid and Insulin Infusions in Healthy and PCOS Women

et al. 2020

View full text Add to dashboard Cite

Background: The fibroblast growth factors (FGF) 19 subfamily, also referred to as endocrine FGFs, includes FGF19, FGF21, and FGF23 are metabolic hormones involved in the regulation of glucose and lipid metabolism. Fetuin-A is a hepatokine involved in the regulation of beta-cell function and insulin resistance. Endocrine FGFs and fetuin-A are dysregulated in metabolic disorders including obesity, type 2 diabetes, non-alcoholic fatty liver disease and polycystic ovary syndrome (PCOS). Our study was designed to examine the response of endocrine FGFs and fetuin-A to an acute intralipid, insulin infusion and exercise in PCOS and healthy women. Subjects and Measurements: Ten healthy and 11 PCOS subjects underwent 5-h saline infusions with a hyperinsulinemic-euglycemic clamp (HIEC) performed during the final 2 h. One week later, intralipid infusions were undertaken with a HIEC performed during the final 2 h. After an 8 week of exercise intervention the saline, intralipid, and HIEC were repeated. Plasma levels of endocrine FGFs and fetuin-A were measured. Results: Baseline fetuin-A was higher in PCOS women but FGF19, FGF21, and FGF23 did not differ and were unaffected by exercise. Insulin administration elevated FGF21 in control and PCOS, suppressed FGF19 in controls, and had no effects on FGF23 and fetuin-A. Intralipid infusion suppressed FGF19 and increased FGF21. Insulin with intralipid synergistically increased FGF21 and did not have effects on lipid-mediated suppression of FGF19 in both groups. Conclusion: Our study provides evidence for insulin and lipid regulation of endocrine FGFs in healthy and PCOS women, suggesting that FGF family members play a role in lipid and glucose metabolism.

show abstract

“…Zhang et al showed that serum FGF19 levels were significantly lower in normal glucose tolerance (NGT) subjects than in isolated-impaired glucose tolerance (I-IGT) subjects and isolated-impaired fasting glucose (I-IFG) participants based on glucose effectiveness (GE) and hepatic glucose production (HGP) [24]. Meanwhile, in T2D patients with MetS, serum FGF19 levels were significantly lower than they were in other T2D patients.…”

Section: Discussionmentioning

confidence: 99%

Association of serum fibroblast growth factor 19 levels with arteriosclerosis parameters assessed by arterial stiffness and atherogenic index of plasma in patients with type 2 diabetes

Liu

Tang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background The role of serum fibroblast growth factor 19 (FGF19) in the arteriosclerosis is not well known. In the present study, we aimed to explore whether serum FGF19 levels were related to the arteriosclerosis parameters, including arterial stiffness and atherogenic index of plasma (AIP), in patients with type 2 diabetes (T2D). Methods 200 patients with type 2 diabetes and 50 healthy controls were recruited for this study from Apr 2017 to Oct 2018. Serum FGF19 levels, arterial stiffness assessed by brachial ankle pulse wave velocity (baPWV), and AIP assessed by ratio of triglyceride to high-density lipoprotein cholesterol (TG/HDL-c) were measured in those subjects. In addition, other relevant clinical data were also collected. Results Serum FGF19 levels in T2D patients were significantly lower than that in healthy controls ( p < 0.01). The arteriosclerosis parameters, including baPWV and AIP, significantly decreased across ascending tertiles of serum FGF19 levels (all p for trend < 0.001). Moreover, the baPWV and AIP were all inversely correlated with serum FGF19 levels ( r = –0.351 and –0.303, respectively, p < 0.001). Furthermore, after adjusting for other clinical covariates by multiple linear regression analyses, the serum FGF19 levels were independently associated with baPWV ( β = –0.20, t = –2.23, p = 0.029) and AIP ( β = –0.28, t = –2.66, p = 0.010) in patients with T2D. Conclusions The serum FGF19 levels were independently and inversely associated with baPWV and AIP in patients with T2D, which indicate serum FGF19 may plays a protect role against pathogenesis of the atherosclerosis in those patients.

show abstract

Decrease of FGF19 contributes to the increase of fasting glucose in human in an insulin-independent manner

Cited by 14 publications

References 41 publications

Serum Fibroblast Growth Factor 19 and Total Bile Acid Concentrations Are Potential Biomarkers of Hepatocellular Carcinoma in Patients with Type 2 Diabetes Mellitus

Serum Fibroblast Growth Factor 19 and Total Bile Acid Concentrations Are Potential Biomarkers of Hepatocellular Carcinoma in Patients with Type 2 Diabetes Mellitus

Dynamic Changes in Circulating Endocrine FGF19 Subfamily and Fetuin-A in Response to Intralipid and Insulin Infusions in Healthy and PCOS Women

Association of serum fibroblast growth factor 19 levels with arteriosclerosis parameters assessed by arterial stiffness and atherogenic index of plasma in patients with type 2 diabetes

Contact Info

Product

Resources

About